European Parliament to vote on new pharmacovigilance proposal on 22 September
This article was originally published in SRA
Executive Summary
The European Parliament appears set to vote in favour of adopting a new legislation that would strengthen the EU pharmacovigilance framework by, among other things, allowing direct patient reporting of adverse drug reactions1,2. The proposed directive, on which the parliament will cast its votes on 22 September, would also allow public authorities to order further efficacy studies of drugs that are already on the market.